ASAmy Steadman

Amy Steadman

*This is an algorithmically generated author record based on publicly available information.

Amy Steadman has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Analytical benchmarking of extraction-free lysis devices for molecular detection of tuberculosis

    by Sonal Jain, Alexey Ball, Caitlin Anderson, Adithya Cattamanchi, Claudia Denkinger, Amy Steadman, Seda Yerlikaya

    Sample preparation remains a barrier for decentralized, swab-based molecular testing of tuberculosis (TB). Extraction-free workflows offer a simpler alternative, but systematic benchmarking against standard methods is lacking. We evaluated five novel lysis devices, BLINK Shaker Prototype, nPOC-BB, SPS-1, Truelyse, and Thermolyse, against a heat- and bead-beating reference method using contrived M. tuberculosis-spiked tongue and sputum swabs. The primary outcome was lysis efficiency, measured as the relative DNA recovery compared with the reference workflow. Secondary outcomes included nuclease inactivation, biosafety, and usability. In the reference buffer, lysis efficiencies ranged from 51-63% to 95-154% on tongue swabs and 12-54% to 280-644% on sputum swabs across the five devices. In proprietary buffers, performance varied more widely, with lysis efficiencies of 2-4% to 64-80% on tongue swabs and 1% to 94-398% on sputum swabs. Complete biosafety inactivation was achieved by three devices; two showed residual growth (<0.02%). Lysis efficiency of several devices met or exceeded the reference, supporting the feasibility of extraction-free workflows for TB diagnosis, with further optimization of buffer compatibility and biosafety profiles expected to enhance performance.

  • Top Cited Papers
    Open Access

    Diagnostic accuracy of swab-based molecular tests for tuberculosis using near-point-of-care platforms: a multi-country evaluation

    by Amy Steadman, Kingsley Manoj Kumar, Lucy Asege, Midori Kato-Maeda, Job Mukwatamundu, Kinari Shah, Trinh Trang, Alexey Ball, Khushboo Khimani, Dao Thi Kim Dung, et al.


  • Open Access

    Diagnostic accuracy of tongue swab testing in persons with sputum Xpert Ultra Trace results

    by Adrienne E. Shapiro, Ronit R Dalmat, Job Mukwatamundu, Caleb Kamoga, M William Ngwane, Amy Steadman, Elvira Budiawan, Gabrielle Stein, Annet Nalutaaya, James Mukiibi, et al.

    Background: Molecular amplification of tongue swab samples is a non-sputum-based investigational approach to diagnose pulmonary tuberculosis (pTB). An improved manual qPCR method for tongue swabs recently achieved >90% sensitivity overall in diagnosing TB, compared to a sputum microbiologic reference standard. Performance characteristics in persons with low-positive results on sputum molecular tests are unknown. Methods: Adults in South Africa and Uganda with sputum Xpert MTB/RIF Ultra Trace (TR+) results were recruited for confirmatory evaluation and follow-up. They underwent symptom evaluation, examination, chest X-ray, further sputum testing (repeat Xpert Ultra and two solid and liquid mycobacterial cultures), and two tongue swabs. Tongue swabs were tested using qPCR amplification of the IS6110 gene. A single copy detected on >=1 swab was considered TB-positive. TR+ persons not diagnosed with TB at baseline were re-evaluated at 1 and 3 months. We determined the sensitivity and specificity of tongue swabs against TB culture alone, a microbiologic reference standard (MRS: any positive result from Xpert Ultra or TB culture) and a composite reference standard (CRS: a clinical recommendation for TB treatment or any positive culture) at baseline. Results: 225 enrolled TR+ participants (115 (51%) women, median age 38 [IQR 30-47], 130 (58%) people living with HIV (PWH)) provided at least 1 tongue swab at baseline. With a culture reference standard, 45 (20%) were positive for TB at baseline testing; 58 (26%) were positive for TB by MRS and 83 (37%) by CRS. Sensitivity and specificity of tongue swabs against culture were 25% [95% CI 13-40%] and 94% [90-97%], vs. MRS were 25% [95% CI 14-38%] and 96% [91-98%], and vs. CRS were 16% [9-26%] and 94% [89-98%]. Conclusion: Tongue swabs had low sensitivity and moderately high specificity for TB in persons with a Trace Xpert Ultra result. Tongue swabs have limited value for diagnosing people with low-positive molecular test results of uncertain clinical significance.


  • Open Access

    Cumulative TB disease burden following sputum Xpert Ultra ‘Trace’ results in clinical settings: Results from a multi-site observational clinical study

    by Ronit R Dalmat, Caitlin Visek, Elvira Budiawan, Gabrielle Stein, Annet Nalutaaya, James Mukiibi, Mariam Nantale, Patrick Biché, Joowhan Sung, Zanele Magcaba, et al.

    Background Highly sensitive molecular tests, like Xpert Ultra, are reshaping TB diagnosis—detecting paucibacillary TB but sometimes creating uncertainty when they detect DNA in extremely low quantities that may not signal disease. This ambiguity also complicates the evaluation of novel diagnostic strategies. We sought to monitor adults with a ‘Trace’ result on an Xpert Ultra test to estimate the risk of tuberculosis disease up to 24 months later. Methods We conducted a multi-site clinical observational study in South Africa and Uganda, where we enrolled ambulatory participants aged >=15 years with a sputum Xpert Ultra Trace result who had not yet initiated TB treatment. All participants underwent comprehensive clinical evaluation and repeated, standard sputum TB testing. Clinicians deferred treatment recommendations if TB status remained uncertain after evaluation. Untreated participants were followed regularly until TB diagnosis and/or treatment initiation. We estimated cumulative incidence of TB disease, defined by three reference standards. Results Of 311 participants with Trace results (50% male, 57% PLHIV, 37% treated for TB within the last 5 years), 24% were positive for TB within 12 months by culture, 37% by sputum Xpert or culture, and 54% by culture or clinical diagnosis. After excluding those diagnosed with TB at baseline, patients identified at baseline as having recent TB history, abnormal chest x-ray, or positive tongue swab, had higher risk of TB diagnosis (hazard ratios: 2.6, 2.4, 4.5, respectively) during follow-up. This hazard was highest in the first three months after the negative baseline evaluation (0.22 [95% CI: 0.19-0.26] per person-month) and decreased to 0.01 [95% CI: 0-0.02] per person-month in both the 3-6 and 6-12-month intervals. Conclusion Approximately half of adults and adolescents with a sputum Trace result were diagnosed with TB disease within twelve months. Although most TB diagnoses were made within 3 months, risk remained higher than estimated population incidence rates through the follow-up period. Individuals with sputum Trace results should receive close clinical monitoring, despite initial clinical treatment decision. Summary results Xpert Ultra “Trace” results detect low quantities of TB DNA, creating diagnostic uncertainty that complicates both clinical decisions and diagnostics evaluation. This clinical observational cohort study followed untreated patients with Trace results for twelve or more months, using survival analysis to estimate actual tuberculosis disease risk and identify risk factors.


  • Open Access

    Diagnostic accuracy of swab-based molecular tests for tuberculosis using novel near point-of-care platforms: A multi-country evaluation

    by Amy Steadman, Kingsley Manoj Kumar, Lucy Asege, Midori Kato-Maeda, Job Mukwatamundu, Kinari Shah, Trinh Trang, Alexey Ball, Khushboo Khimani, Dao Thi Kim Dung, et al.

    Background Swab-based molecular platforms that enable testing of both sputum (via swabs swirled in sputum) and tongue swabs are emerging as a promising option for more accessible and lower cost molecular testing for tuberculosis (TB). We conducted a multi-country evaluation of two novel swab-based molecular tests: Molbio Truenat MTB Ultima (MTB Ultima) and Pluslife MiniDock MTB Test (MiniDock MTB). Methods Consecutive people ≥12 years old with presumptive TB were enrolled at outpatient health centers in India, Uganda, and Vietnam. We collected two tongue swabs and prepared two sputum swabs for MTB Ultima and MiniDock MTB testing, then evaluated the diagnostic accuracy of MTB Ultima and MiniDock MTB using both swab types against a sputum liquid culture-based microbiological reference standard (MRS). The diagnostic accuracy of swab-based molecular tests was also compared to sputum Xpert MTB/RIF Ultra (Xpert Ultra) and auramine smear microscopy. Findings From January to September 2024, 1,050 participants were included in the tongue swab MTB Ultima evaluation, 197 in the sputum swab MTB Ultima evaluation, and 322 in the MiniDock MTB evaluations. In comparison to sputum Xpert Ultra, sensitivity was similar for both sputum swab MTB Ultima (93.6% vs. 100.0%, difference -6.4%, [95% CI: -15.5, 2.7], p=0.25) and MiniDock MTB (91.0% vs. 94.0%, difference –3.0% [95% CI: -8.6, 2.6], p=0.50). In comparison to sputum smear microscopy, sensitivity was higher for both tongue swab MTB Ultima (77.9% vs. 59.1%, difference 18.8% [95% CI: 10.8, 26.8], p98%) for both tests with sputum swabs and tongue swabs. Interpretation MTB Ultima and MiniDock MTB have similar accuracy to current sputum-based molecular tests with sputum swabs and meet minimum accuracy thresholds for a non-sputum, near point-of-care molecular test with tongue swabs. These tests offer strong potential to make universal molecular testing for TB a reality.


  • Open Access

    Xpert MTB/RIF Ultra testing from tongue swabs – Diluted SR method v1

    by Charlotte Ahls, Anura David, Gayatri Shankar Chilambi, Adithya Cattamanchi, Margaretha de Vos, Kelsey Heard, Karen Heichman, Adam Penn-Nicholson, Lesley Scott, Amy E Steadman, et al.

    This standard operating procedure (SOP) outlines the methodology for processing dry dorsum tongue swabs with Xpert MTB/RIF Ultra (Ultra) (Cepheid, Sunnyvale, CA). The procedure is intended as a consensus protocol for clinical evidence generation to evaluate whether tongue swabs can be used as an additional sample type to diagnose tuberculosis (TB) using Ultra. Tongue swabs will be collected for Ultra testing at the clinical facility. Please refer to the tongue swab collection SOP. Several groups have shown that the use of Xpert Sample Reagent (SR) at a starting concentration of 100% can result in decreased sensitivity for the detection of Mycobacterium tuberculosis from tongue swabs. This protocol makes use of diluted SR in phosphate buffer (PB), with a starting concentration of SR of 66%.


  • Open Access

    Consensus standard operating procedure for collection of tongue swabs for TB diagnostics v1

    by Alfred Andama, Amy E Steadman, Charlotte Ahls, Gerard Cangelosi, Anura David, Margaretha de Vos, Karen Heichman, Midori Kato-Maeda, Adam Penn-Nicholson, Alaina Olson, et al.

    This standard operating procedure (SOP) outlines the methodology for the collection of tongue swabs for subsequent testing of tuberculosis molecular assays that require a dry swab as input material.


  • Top Cited Papers
    Open Access

    New Manual Quantitative Polymerase Chain Reaction Assay Validated on Tongue Swabs Collected and Processed in Uganda Shows Sensitivity That Rivals Sputum-based Molecular Tuberculosis Diagnostics

    by Amy Steadman, Alfred Andama, Alexey Ball, Job Mukwatamundu, Khushboo Khimani, Tessa Mochizuki, Lucy Asege, Alice Bukirwa, John Baptist Kato, David Katumba, et al.

    Background: Sputum-based testing is a barrier to increasing access to molecular diagnostics for tuberculosis (TB). Many people with TB are unable to produce sputum, and sputum processing increases assay complexity and cost. Tongue swabs are emerging as an alternative to sputum, but performance limits are uncertain. Methods: From June 2022 to July 2023, we enrolled 397 consecutive adults with cough >2 weeks at 2 health centers in Kampala, Uganda. We collected demographic and clinical information, sputum for TB testing (Xpert MTB/RIF Ultra and 2 liquid cultures), and tongue swabs for same-day quantitative polymerase chain reaction (qPCR) testing. We evaluated tongue swab qPCR diagnostic accuracy versus sputum TB test results, quantified TB targets per swab, assessed the impact of serial swabbing, and compared 2 swab types (Copan FLOQSWAB and Steripack spun polyester). Results: Among 397 participants, 43.1% were female, median age was 33 years, 23.5% were diagnosed with human immunodeficiency virus, and 32.0% had confirmed TB. Sputum Xpert Ultra and tongue swab qPCR results were concordant for 98.2% (95% confidence interval [CI]: 96.2–99.1) of participants. Tongue swab qPCR sensitivity was 92.6% (95% CI: 86.5 to 96.0) and specificity was 99.1% (95% CI: 96.9 to 99.8) versus microbiological reference standard. A single tongue swab recovered a 7-log range of TB copies, with a decreasing recovery trend among 4 serial swabs. Swab types performed equivalently. Conclusions: Tongue swabs are a promising alternative to sputum for molecular diagnosis of TB, with sensitivity approaching sputum-based molecular tests. Our results provide valuable insights for developing successful tongue swab–based TB diagnostics.


  • Open Access

    New manual qPCR assay validated on tongue swabs collected and processed in Uganda shows sensitivity that rivals sputum-based molecular TB diagnostics

    by Amy Steadman, Alfred Andama, Alexey Ball, Job Mukwatamundu, Khushboo Khimani, Tessa Mochizuki, Lucy Asege, Alice Bukirwa, John Baptist Kato, David Katumba, et al.

    Background: Reliance on sputum-based testing is a key barrier to increasing access to molecular diagnostics for tuberculosis (TB). Many people with TB are unable to produce and sputum processing increases the complexity and cost of molecular assays. Tongue swabs are emerging as an alternative to sputum, but performance limits are uncertain. Methods: From June 2022 to July 2023, we enrolled 397 consecutive adults with cough >2 weeks at two health centers in Kampala, Uganda. We collected routine demographic and clinical information, sputum for routine TB testing (one Xpert MTB/RIF Ultra® and two liquid cultures), and up to four tongue swabs for same-day qPCR. We evaluated tongue swab qPCR diagnostic accuracy in reference to sputum TB test results, quantified TB targets per swab, assessed the impact of serial swabbing, and compared two swab types (Copan FLOQSWAB® and Steripack® spun polyester swabs). Results: Among 397 participants, 43.1% were female, median age was 33 years, 23.5% were living with HIV (PLHIV) and 32.3% had confirmed TB. Sputum Xpert Ultra and tongue swab qPCR results were concordant for 98.2% [96.2-99.1] of participants. Tongue swab qPCR sensitivity was 91.0% [84.6-94.9] and specificity 98.9% [96.2-99.8] vs. microbiological reference standard (MRS). A single tongue swab recovered a seven-log range of TB copies, with a decreasing recovery trend among four serial swabs. We found no difference between swab types. Conclusions: Tongue swabs show promise as an alternative to sputum for TB diagnosis, with sensitivity approaching sputum-based molecular tests. Our results provide valuable insights for developing successful tongue swab-based TB diagnostics.